Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 In vitro susceptibilities of Chlamydia pneumoniae (Chlamydia sp. strain TWAR).

Literature DB >> 2817862

In vitro susceptibilities of Chlamydia pneumoniae (Chlamydia sp. strain TWAR).

K Chirgwin¹, P M Roblin, M R Hammerschlag.

Abstract

The in vitro susceptibilities of two clinical isolates of Chlamydia pneumoniae from Brooklyn, N.Y., were determined for tetracycline, erythromycin, sulfamethoxazole, ciprofloxacin, and three new macrolides--azithromycin, clarithromycin, and roxithromycin. Clarithromycin was the most active drug tested, followed by the other macrolides, tetracycline, and ciprofloxacin.

Entities: Chemical Species

Mesh：

Substances：
Anti-Bacterial Agents

Year: 1989 PMID： 2817862 PMCID： PMC172720 DOI： 10.1128/AAC.33.9.1634

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

5 in total

1. In vitro drug susceptibility of Chlamydia sp. strain TWAR.

Authors: C C Kuo; J T Grayston
Journal: Antimicrob Agents Chemother Date: 1988-02 Impact factor: 5.191

2. Pneumonia associated with the TWAR strain of Chlamydia.

Authors: T J Marrie; J T Grayston; S P Wang; C C Kuo
Journal: Ann Intern Med Date: 1987-04 Impact factor: 25.391

3. An epidemic of mild pneumonia due to an unusual strain of Chlamydia psittaci.

Authors: P Saikku; S P Wang; M Kleemola; E Brander; E Rusanen; J T Grayston
Journal: J Infect Dis Date: 1985-05 Impact factor: 5.226

4. A new Chlamydia psittaci strain, TWAR, isolated in acute respiratory tract infections.

Authors: J T Grayston; C C Kuo; S P Wang; J Altman
Journal: N Engl J Med Date: 1986-07-17 Impact factor: 91.245

5. In vitro susceptibilities of mycoplasmas and ureaplasmas to new macrolides and aryl-fluoroquinolones.

Authors: K B Waites; G H Cassell; K C Canupp; P B Fernandes
Journal: Antimicrob Agents Chemother Date: 1988-10 Impact factor: 5.191

5 in total

21 in total

1. In vitro evaluation of activities of azithromycin, erythromycin, and tetracycline against Chlamydia trachomatis and Chlamydia pneumoniae.

Authors: L E Welsh; C A Gaydos; T C Quinn
Journal: Antimicrob Agents Chemother Date: 1992-02 Impact factor: 5.191

2. Antibiotic resistance in common acute respiratory pathogens.

Authors: P Venkatesan; J A Innes
Journal: Thorax Date: 1995-05 Impact factor: 9.139

3. In vitro activity of a new 8-methoxyquinolone, BAY 12-8039, against Chlamydia pneumoniae.

Authors: P M Roblin; M R Hammerschlag
Journal: Antimicrob Agents Chemother Date: 1998-04 Impact factor: 5.191

4. Comparison of three-day and five-day courses of azithromycin in the treatment of atypical pneumonia.

Authors: S Schönwald; V Skerk; I Petricevic; V Car; L Majerus-Misic; M Gunjaca
Journal: Eur J Clin Microbiol Infect Dis Date: 1991-10 Impact factor: 3.267

5. In vitro and in vivo antichlamydial activities of newly developed quinolone antimicrobial agents.

Authors: M Kimura; T Kishimoto; Y Niki; R Soejima
Journal: Antimicrob Agents Chemother Date: 1993-04 Impact factor: 5.191

6. Telithromycin treatment of chronic Chlamydia pneumoniae infection in C57BL/6J mice.

Authors: Liisa Törmäkangas; Hannu Alakärppä; Denise Bem David; Maija Leinonen; Pekka Saikku
Journal: Antimicrob Agents Chemother Date: 2004-10 Impact factor: 5.191

7. In vitro susceptibilities of spotted fever group rickettsiae and Coxiella burnetti to clarithromycin.

Authors: M Maurin; D Raoult
Journal: Antimicrob Agents Chemother Date: 1993-12 Impact factor: 5.191

8. In vitro activity of azithromycin (CP-62,993) against Chlamydia trachomatis and Chlamydia pneumoniae.

Authors: A Agacfidan; J Moncada; J Schachter
Journal: Antimicrob Agents Chemother Date: 1993-09 Impact factor: 5.191

Review 9. Quinolones in the treatment of lower respiratory tract infections caused by intracellular pathogens.

Authors: C Chidiac; Y Mouton
Journal: Infection Date: 1991 Impact factor: 3.553

Review 10. Azithromycin. A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy.

Authors: D H Peters; H A Friedel; D McTavish
Journal: Drugs Date: 1992-11 Impact factor: 9.546